China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its VUM02, a Category 1 therapeutic biologic product. This human umbilical cord-derived mesenchymal stem cell therapy is intended to treat Grade II to IV steroid-refractory acute graft versus host disease (SR-aGvHD), a significant step in addressing a critical unmet medical need.
Current Landscape and VUM02’s Potential
While products like Prochymal (approved in Canada and New Zealand in 2012) and Temcell (approved in Japan in 2015) are available for treating SR-aGvHD, there is currently no such approved product in China. VUM02’s entry into clinical studies signifies a potential breakthrough in the treatment landscape for SR-aGvHD in the Chinese market.
Understanding SR-aGvHD and Treatment Challenges
Acute graft versus host disease (aGvHD) is a major comorbidity and cause of death following allogeneic hematopoietic stem cell transplantation (allo-HSCT), often occurring due to histocompatibility differences between donors and recipients. Moderate to severe aGvHD can occur in 13% to 47% of cases, with a particularly poor prognosis for patients who have failed hormone therapy. The standard first-line treatment, glucocorticoids, has an effective rate of only 30% to 50%, highlighting the urgent need for more effective therapies like VUM02.-Fineline Info & Tech
